Synopsis
Synopsis
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. H 168 68
2. H 168-68
3. H 16868
4. Magnesium, Omeprazole
5. Omeprazole Magnesium
6. Omeprazole Sodium
7. Prilosec
8. Sodium, Omeprazole
1. 73590-58-6
2. Losec
3. Prilosec
4. Esomeprazole
5. Antra
6. Omeprazon
7. Audazol
8. Omapren
9. Omepral
10. Parizac
11. Zegerid
12. Mopral
13. Miol
14. Belmazol
15. Ceprandal
16. Dizprazol
17. Dudencer
18. Emeproton
19. Epirazole
20. Gastrimut
21. Gastroloc
22. Gibancer
23. Indurgan
24. Inhibitron
25. Inhipump
26. Logastric
27. Pepticum
28. Peptilcer
29. Prazidec
30. Sanamidol
31. Secrepina
32. Ulcometion
33. Mepral
34. Miracid
35. Omeprol
36. Omezol
37. Omisec
38. Omizac
39. Ompanyt
40. Ozoken
41. Prysma
42. Ramezol
43. Ulceral
44. Ulcesep
45. Ulcozol
46. Zefxon
47. Zoltum
48. Desec
49. Elgam
50. Lomac
51. Ulsen
52. Ultop
53. Zimor
54. Ocid
55. Omed
56. Omid
57. Omep
58. Demeprazol
59. Nopramin
60. Omeprazol
61. Omezolan
62. Paprazol
63. Pepticus
64. Prazentol
65. Prazolit
66. Procelac
67. Regulacid
68. Danlox
69. Erbolin
70. Lensor
71. Morecon
72. Nilsec
73. Olexin
74. Omegast
75. Omesek
76. Ortanol
77. Osiren
78. Proclor
79. Result
80. Ulcsep
81. Victrix
82. Zepral
83. Exter
84. Gasec
85. Ulzol
86. Omebeta 20
87. Tedec Ulceral
88. Aulcer
89. Antra Mups
90. Omerprazole
91. Omez
92. 119141-88-7
93. Omepradex
94. Omeprazolum
95. H 168/68
96. Gastrogard
97. Nuclosina
98. Omesec
99. Omeprazole-d3
100. Mfcd00083192
101. Prestwick_808
102. 5-methoxy-2-(((4-methoxy-3,5-dimethyl-2-pyridyl)methyl)sulfinyl)benzimidazole
103. 6-methoxy-2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)-1h-benzo[d]imidazole
104. H-168/68
105. Omz
106. Chebi:77260
107. 119141-89-8
108. 6-methoxy-2-[(4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl]-1h-benzimidazole
109. 1h-benzimidazole, 5-methoxy-2-(((4-methoxy-3,5-dimethyl-2-pyridinyl)methyl)sulfinyl)-
110. Aisi'aomeilazuona Esomeprazole Sodium
111. Nsc-751450
112. Nsc-759192
113. Chembl1503
114. Nexiam
115. Esomeprazole Sodium Salt
116. 5-methoxy-2-[(4-methoxy-3,5-dimethylpyridin-2-yl)methanesulfinyl]-1h-1,3-benzodiazole
117. 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1h-benzimidazole
118. 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1h-benzimidazole
119. Mls000069373
120. Kg60484qx9
121. 73590-58-6 (free Form)
122. Omeprazol [inn-spanish]
123. Omeprazolum [inn-latin]
124. Ncgc00016925-06
125. Esomperazole
126. Smr000058847
127. Emilok
128. Cas-73590-58-6
129. Dsstox_cid_1080
130. 2-({[3,5-dimethyl-4-(methyloxy)pyridin-2-yl]methyl}sulfinyl)-5-(methyloxy)-1h-benzimidazole
131. 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methane]sulfinyl}-1h-1,3-benzodiazole
132. Dsstox_rid_75929
133. Dsstox_gsid_21080
134. ( -)-omeprazole
135. (r)-5-methoxy-2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)-1h-benzo[d]imidazole
136. Omeprazone
137. Omeprazen
138. Omeprazole Delayed-release
139. Omeprazole Pellets
140. 5-methoxy-2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)-1h-benzo[d]imidazole
141. 5-methoxy-2-((4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl)-1h-benzo[d]imidazole
142. 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridyl)methylsulfinyl]-1h-benzimidazole
143. 5-methoxy-2-[(4-methoxy-3,5-dimethyl-pyridin-2-yl)methylsulfinyl]-3h-benzoimidazole
144. 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridyl)methyl]sulfinyl]benzimidazole
145. Prilosec (tn)
146. (+-)-omeprazole
147. Ccris 7099
148. Hsdb 3575
149. Sr-01000003003
150. Unii-kg60484qx9
151. Omeprazole-d6
152. Omeprazole, Solid
153. 5-methoxy-2-[(4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl]-1h-benzimidazole
154. Agi-010
155. Omeprazole,(s)
156. Omeprazole Solution
157. Omeprazole-[d3]
158. (rs)-6-methoxy-2-((4-methoxy-3,5-dimethylpyridin-2-yl) Methylsulfinyl)-1h-benzo(d)imidazole
159. (rs)-6-methoxy-2-((4-methoxy-3,5-dimethylpyridin-2-yl) Methylsulfinyl)-1h-benzo[d]imidazole
160. 326602-80-6
161. Omeprazole S-isomer
162. 2-(((3,5-dimethyl-4-methoxy-2-pyridyl)methyl)sulfinyl)-5-methoxy-1h-benzimidazole
163. Omeprazole - Bio-x
164. Dm-3458
165. Omeprazole [usan:usp:inn:ban:jan]
166. Omeprazole-13c,d3
167. Omeprazole (prilosec)
168. Omeprazole [mi]
169. Omeprazole [inn]
170. Omeprazole [jan]
171. Maybridge4_002645
172. Opera_id_1863
173. Prestwick0_000493
174. Prestwick1_000493
175. Prestwick2_000493
176. Prestwick3_000493
177. (.+/-.)-omeprazole
178. Omeprazole [hsdb]
179. Omeprazole [usan]
180. O0359
181. Omeprazole [vandf]
182. Upcmld-dp075
183. Cid_4594
184. Omeprazole [mart.]
185. Schembl1191
186. Omeprazole [usp-rs]
187. Omeprazole [who-dd]
188. H 16868
189. Bspbio_000385
190. Mls001076112
191. Mls001424148
192. Mls006010400
193. Mls006011759
194. Bidd:gt0189
195. Spbio_002306
196. Bpbio1_000425
197. Gtpl4279
198. Omeprazole (jp17/usp/inn)
199. Omeprazole [green Book]
200. Dtxsid6021080
201. Omeprazole [orange Book]
202. Schembl11995456
203. Upcmld-dp075:001
204. Chebi:91766
205. Omeprazole [usp Impurity]
206. Hms1528i05
207. Hms1569d07
208. Hms2052g17
209. Hms2090e16
210. Hms2090f11
211. Hms2096d07
212. Hms2232b21
213. Hms3269d17
214. Hms3394g17
215. Hms3413j07
216. Hms3651a11
217. Hms3677j07
218. Hms3713d07
219. Omeprazole [usp Monograph]
220. Pharmakon1600-01505693
221. Zegerid Component Omeprazole
222. Amy30573
223. Bcp05852
224. Bcp13592
225. Bcp21299
226. Hy-b0113
227. Yosprala Component Omeprazole
228. 2,3,5-trimethylpyridine/omeprazole
229. Tox21_110686
230. Tox21_200509
231. Ac-401
232. Bbl028172
233. Bdbm50103597
234. Bdbm50241343
235. Dl-462
236. Mfcd23135254
237. Nsc751450
238. Nsc759192
239. S1389
240. Stk623746
241. Akos005066653
242. Akos015895343
243. Omeprazole Component Of Zegerid
244. Tox21_110686_1
245. Ac-4676
246. Ccg-101130
247. Ccg-213517
248. Cs-1868
249. Db00338
250. Hs-0055
251. Nc00380
252. Nsc 751450
253. Nsc 759192
254. Omeprazole Component Of Yosprala
255. (s)-5-methoxy-2-[(4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl]-3h-benzoimidazole
256. Idi1_032523
257. Ncgc00016925-01
258. Ncgc00016925-02
259. Ncgc00016925-03
260. Ncgc00016925-04
261. Ncgc00016925-05
262. Ncgc00016925-07
263. Ncgc00016925-08
264. Ncgc00016925-10
265. Ncgc00016925-11
266. Ncgc00021522-03
267. Ncgc00021522-04
268. Ncgc00021522-05
269. Ncgc00258063-01
270. Omeprazole, Analytical Reference Material
271. Bo164173
272. Sy009746
273. Sy077145
274. Sbi-0206896.p001
275. Ft-0601585
276. Ft-0652860
277. Ft-0653294
278. Ft-0673283
279. Ft-0689771
280. H 199
281. Sw196942-4
282. A19447
283. C07324
284. D00455
285. 141o887
286. A837865
287. A892647
288. A937349
289. Q422210
290. Sr-01000003003-4
291. Sr-01000003003-7
292. Sr-01000003003-8
293. 5-methoxy-2-((4-methoxy-3,5-dimethylpyridin-2-yl)
294. Brd-a55962179-001-04-9
295. Brd-a55962179-001-08-0
296. Brd-a55962179-001-20-5
297. Brd-a88691025-001-07-4
298. F0001-2386
299. Z1672902589
300. Omeprazole, British Pharmacopoeia (bp) Reference Standard
301. Omeprazole, European Pharmacopoeia (ep) Reference Standard
302. Omeprazole, United States Pharmacopeia (usp) Reference Standard
303. 2-(3-methoxy-2,4-dimethylbenzylsulfinyl)-6-methoxy-1h-benzo[d]imidazole
304. 5-methoxy-2-((s)-((4-methoxy-3,5-dimethyl-2- Pyridinyl)methyl)sulfinyl)-
305. Omeprazole, Pharmaceutical Secondary Standard; Certified Reference Material
306. (+)-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]-sulfinyl]-1h-benzimidazole
307. (-)-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]-sulfinyl]-1h-benzimidazole
308. (rs)-5-methoxy-2-(4-methoxy-3,5-dimethyl-2-pyridylmethylsulphinyl)benzimidazole
309. 1h-benzimidazole,5-methoxy-2-[(r)-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-
310. 5-methoxy 2-[[(4-methoxy-3,5-dimethyl-2-pyrdinyl)-methyl]sulfinyl]-1h-benzimidazole
311. 5-methoxy 2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1 H-benzimidazole
312. 5-methoxy 2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1h-benzimidazole
313. 5-methoxy-2-(2-(4-methoxy-3,5-dimethylpyridin-2-yl)ethylsulfinyl)-1h-benzo[d]imidazole
314. 5-methoxy-2-(4-methoxy-3,5-dimethyl-pyridin-2-ylmethanesulfinyl)-1h-benzoimidazole
315. 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridyl)methyl]sulfinyl- 1h-benzimidazole
316. 5-methoxy-2-[[(3,5-dimethyl-4-methoxy-2-pyridyl)methyl]sulfinyl]-1h-benzimidazole
317. 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulphinyl]-1h-benzimidazole
318. 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridyl)methyl]sulfinyl]-benzimidazole
319. 5-methoxy-2-[[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulphinyl]1h-benzimidazole
320. 6-methoxy-2-(((4-methoxy-3,5-dimethyl Pyridin-2-yl)methyl)sulfinyl)-1h-benzo[d]imidazole
321. 6-methoxy-2-((4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl)-1h-benzo[d]imidazole
322. 6-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methylsulfinyl]-1h-benzimidazole
323. 6-methoxy-2-[(4-methoxy-3,5-dimethyl-pyridin-2-yl)methylsulfinyl]-1h-benzimidazole
324. 6-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1h-benzimidazole
325. 6-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1h-benzimidazole
326. 6-methoxy-2-[[(4-methoxy-3,5dimethyl-2-pyridinyl)-methyl]sulfinyl]-1h-benzimidazole
327. 6-methoxy-2-[[(4-methoxy3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1h-benzimidazole
328. 6-methoxy-2-[[(4methoxy-3,5-dimethyl2-pyridinyl)methyl]sulfinyl]-1h-benzimidazole
329. Omeprazole For Peak Identification, European Pharmacopoeia (ep) Reference Standard
330. Omeprazole Solution, 1.0 Mg/ml In Methanol, Ampule Of 1 Ml, Certified Reference Material
331. (omeprazole)5-methoxy-2-(4-methoxy-3,5-dimethyl-pyridin-2-ylmethanesulfinyl)-1h-benzoimidazole
332. 1h-benzimidazole,6-methoxy-2-[(r)-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-
333. 5-methoxy-2-(((4-methoxy-3,5,-dimethyl-2-pyridinyl)-methyl)sulphinyl)-1h-benzimidazole
334. 5-methoxy-2-(4-methoxy-3,5-dimethyl-pyridin-2-ylmethanesulfinyl)-1h-benzoimidazole (omeprazole)
335. 5-methoxy-2-(4-methoxy-3,5-dimethyl-pyridin-2-ylmethanesulfinyl)-1h-benzoimidazole(omeprazole)
Molecular Weight | 345.4 g/mol |
---|---|
Molecular Formula | C17H19N3O3S |
XLogP3 | 2.2 |
Hydrogen Bond Donor Count | 1 |
Hydrogen Bond Acceptor Count | 6 |
Rotatable Bond Count | 5 |
Exact Mass | 345.11471265 g/mol |
Monoisotopic Mass | 345.11471265 g/mol |
Topological Polar Surface Area | 96.3 Ų |
Heavy Atom Count | 24 |
Formal Charge | 0 |
Complexity | 453 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 1 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
1 of 14 | |
---|---|
Drug Name | Nexium |
PubMed Health | Esomeprazole |
Drug Classes | Gastric Acid Secretion Inhibitor, Gastrointestinal Agent |
Active Ingredient | Esomeprazole magnesium |
Dosage Form | Capsule, delayed rel pellets; For suspension, delayed release |
Route | Oral |
Strength | eq 5mg base/packet; eq 20mg base/packet; eq 20mg base; eq 40mg base; eq 10mg base/packet; eq 40mg base/packet; eq 2.5mg base/packet |
Market Status | Prescription |
Company | Astrazeneca |
2 of 14 | |
---|---|
Drug Name | Nexium iv |
PubMed Health | Omeprazole (By mouth) |
Drug Classes | Gastric Acid Secretion Inhibitor |
Drug Label | The active ingredient in Omeprazole Delayed-Release Capsules is a substituted benzimidazole, 5-methoxy-2-[[(4-methoxy-3, 5-dimethyl-2-pyridinyl) methyl] sulfinyl]-1H-benzimidazole, a compound that inhibits gastric acid secretion. Its empirical formul... |
Active Ingredient | Esomeprazole sodium |
Dosage Form | Injectable |
Route | Intravenous |
Strength | eq 20mg base/vial; eq 40mg base/vial |
Market Status | Prescription |
Company | Astrazeneca |
3 of 14 | |
---|---|
Drug Name | Omeprazole |
PubMed Health | Omeprazole (By mouth) |
Drug Classes | Gastric Acid Secretion Inhibitor |
Drug Label | 11 DESCRIPTIONThe active ingredient in PRILOSEC (omeprazole) Delayed-Release Capsules is a substituted benzimidazole, 5-methoxy-2-[[(4-methoxy-3, 5-dimethyl-2-pyridinyl) methyl] sulfinyl]-1H-benzimidazole, a compound that inhibits gastric acid secret... |
Active Ingredient | Omeprazole |
Dosage Form | Capsule, delayed rel pellets; Tablet, delayed release |
Route | oral; Oral |
Strength | 10mg; 40mg; 20mg |
Market Status | Tentative Approval; Over the Counter; Prescription |
Company | Actavis Labs Fl; Apotex; Sandoz; Kremers Urban Pharms; Zydus Pharms Usa; Dr Reddys Labs; Dexcel Pharma; Mylan; Impax Labs |
4 of 14 | |
---|---|
Drug Name | Omeprazole magnesium |
PubMed Health | Omeprazole/Sodium Bicarbonate (By mouth) |
Drug Classes | Gastric Acid Secretion Inhibitor |
Drug Label | 11 DESCRIPTIONThe active ingredient in PRILOSEC (omeprazole) Delayed-Release Capsules is a substituted benzimidazole, 5-methoxy-2-[[(4-methoxy-3, 5-dimethyl-2-pyridinyl) methyl] sulfinyl]-1H-benzimidazole, a compound that inhibits gastric acid secret... |
Active Ingredient | Omeprazole magnesium |
Dosage Form | Capsule, delayed release |
Route | Oral |
Strength | eq 20mg base |
Market Status | Over the Counter |
Company | Dr Reddys Labs |
5 of 14 | |
---|---|
Drug Name | Prilosec |
Active Ingredient | Omeprazole magnesium; Omeprazole |
Dosage Form | Capsule, delayed rel pellets; For suspension, delayed release |
Route | Oral |
Strength | eq 10mg base/packet; 10mg; 40mg; 20mg; eq 2.5mg base/packet |
Market Status | Prescription |
Company | Astrazeneca |
6 of 14 | |
---|---|
Drug Name | Prilosec otc |
Active Ingredient | Omeprazole magnesium |
Dosage Form | Tablet, delayed release |
Route | Oral |
Strength | eq 20mg base |
Market Status | Over the Counter |
Company | Astrazeneca |
7 of 14 | |
---|---|
Drug Name | Zegerid |
Active Ingredient | sodium bicarbonate; Omeprazole |
Dosage Form | Capsule; For suspension |
Route | Oral |
Strength | 20mg/packet; 1.1gm; 40mg/packet; 1.68gm/packet; 40mg; 20mg |
Market Status | Prescription |
Company | Santarus |
8 of 14 | |
---|---|
Drug Name | Nexium |
PubMed Health | Esomeprazole |
Drug Classes | Gastric Acid Secretion Inhibitor, Gastrointestinal Agent |
Active Ingredient | Esomeprazole magnesium |
Dosage Form | Capsule, delayed rel pellets; For suspension, delayed release |
Route | Oral |
Strength | eq 5mg base/packet; eq 20mg base/packet; eq 20mg base; eq 40mg base; eq 10mg base/packet; eq 40mg base/packet; eq 2.5mg base/packet |
Market Status | Prescription |
Company | Astrazeneca |
9 of 14 | |
---|---|
Drug Name | Nexium iv |
PubMed Health | Omeprazole (By mouth) |
Drug Classes | Gastric Acid Secretion Inhibitor |
Drug Label | The active ingredient in Omeprazole Delayed-Release Capsules is a substituted benzimidazole, 5-methoxy-2-[[(4-methoxy-3, 5-dimethyl-2-pyridinyl) methyl] sulfinyl]-1H-benzimidazole, a compound that inhibits gastric acid secretion. Its empirical formul... |
Active Ingredient | Esomeprazole sodium |
Dosage Form | Injectable |
Route | Intravenous |
Strength | eq 20mg base/vial; eq 40mg base/vial |
Market Status | Prescription |
Company | Astrazeneca |
10 of 14 | |
---|---|
Drug Name | Omeprazole |
PubMed Health | Omeprazole (By mouth) |
Drug Classes | Gastric Acid Secretion Inhibitor |
Drug Label | 11 DESCRIPTIONThe active ingredient in PRILOSEC (omeprazole) Delayed-Release Capsules is a substituted benzimidazole, 5-methoxy-2-[[(4-methoxy-3, 5-dimethyl-2-pyridinyl) methyl] sulfinyl]-1H-benzimidazole, a compound that inhibits gastric acid secret... |
Active Ingredient | Omeprazole |
Dosage Form | Capsule, delayed rel pellets; Tablet, delayed release |
Route | oral; Oral |
Strength | 10mg; 40mg; 20mg |
Market Status | Tentative Approval; Over the Counter; Prescription |
Company | Actavis Labs Fl; Apotex; Sandoz; Kremers Urban Pharms; Zydus Pharms Usa; Dr Reddys Labs; Dexcel Pharma; Mylan; Impax Labs |
11 of 14 | |
---|---|
Drug Name | Omeprazole magnesium |
PubMed Health | Omeprazole/Sodium Bicarbonate (By mouth) |
Drug Classes | Gastric Acid Secretion Inhibitor |
Drug Label | 11 DESCRIPTIONThe active ingredient in PRILOSEC (omeprazole) Delayed-Release Capsules is a substituted benzimidazole, 5-methoxy-2-[[(4-methoxy-3, 5-dimethyl-2-pyridinyl) methyl] sulfinyl]-1H-benzimidazole, a compound that inhibits gastric acid secret... |
Active Ingredient | Omeprazole magnesium |
Dosage Form | Capsule, delayed release |
Route | Oral |
Strength | eq 20mg base |
Market Status | Over the Counter |
Company | Dr Reddys Labs |
12 of 14 | |
---|---|
Drug Name | Prilosec |
Active Ingredient | Omeprazole magnesium; Omeprazole |
Dosage Form | Capsule, delayed rel pellets; For suspension, delayed release |
Route | Oral |
Strength | eq 10mg base/packet; 10mg; 40mg; 20mg; eq 2.5mg base/packet |
Market Status | Prescription |
Company | Astrazeneca |
13 of 14 | |
---|---|
Drug Name | Prilosec otc |
Active Ingredient | Omeprazole magnesium |
Dosage Form | Tablet, delayed release |
Route | Oral |
Strength | eq 20mg base |
Market Status | Over the Counter |
Company | Astrazeneca |
14 of 14 | |
---|---|
Drug Name | Zegerid |
Active Ingredient | sodium bicarbonate; Omeprazole |
Dosage Form | Capsule; For suspension |
Route | Oral |
Strength | 20mg/packet; 1.1gm; 40mg/packet; 1.68gm/packet; 40mg; 20mg |
Market Status | Prescription |
Company | Santarus |
Anti-Ulcer Agents; Enzyme Inhibitors
National Library of Medicine's Medical Subject Headings online file (MeSH, 1999)
Omeprazole is indicated for the treatment of a complex of symptoms which may be caused by any of the conditions where a reduction of gastric acid secretion is required (e.g., duodenal ulcer, gastric ulcer, nonsteroidal anti-inflammatory drugs associated gastric and duodenal ulcer, reflux esophagitis, gastroesophageal reflex disease) or when no identifiable organic cause is found (i.e., functional dyspepsia). /Included in US product labeling/
Thomson.Micromedex. Drug Information for the Health Care Professional. 24th ed. Volume 1. Plus Updates. Content Reviewed by the United States Pharmacopeial Convention, Inc. Greenwood Village, CO. 2004., p. 2131
Omeprazole is indicated for the treatment of heartburn and other symptoms associated with gastroesophageal reflux disease. Omeprazole is indicated for the short-term treatment of erosive esophagitis (associated with gastroesophageal reflux disease) that has been diagnosed by endoscopy. Omeprazole also is indicated to maintain healing of erosive esophagitis. /Included in US product labeling/
Thomson.Micromedex. Drug Information for the Health Care Professional. 24th ed. Volume 1. Plus Updates. Content Reviewed by the United States Pharmacopeial Convention, Inc. Greenwood Village, CO. 2004., p. 2131
Omeprazole is indicated for the long-term treatment of pathologic gastric hypersecretion associated with Zollinger-Ellison syndrome (alone or as part of multiple endocrine neoplasia Type-1), systemic mastocytosis, and multiple endocrine adenoma. /Included in US product labeling/
Thomson.Micromedex. Drug Information for the Health Care Professional. 24th ed. Volume 1. Plus Updates. Content Reviewed by the United States Pharmacopeial Convention, Inc. Greenwood Village, CO. 2004., p. 2131
For more Therapeutic Uses (Complete) data for OMEPRAZOLE (8 total), please visit the HSDB record page.
Pregnancy risk category: C /RISK CANNOT BE RULED OUT. Adequate, well controlled human studies are lacking, and animal studies have shown risk to the fetus or are lacking as well. There is a chance of fetal harm if the drug is given during pregnancy; but the potential benefits may outweigh the potential risk./
Thomson.Micromedex. Drug Information for the Health Care Professional. 24th ed. Volume 1. Plus Updates. Content Reviewed by the United States Pharmacopeial Convention, Inc. Greenwood Village, CO. 2004., p. 2132
No information is available on the relationship of age to the effects of omeprazole in geriatric patients. However, a somewhat decreased rate of elimination and increased bioavailability are more likely to occur in geriatric patients taking omeprazole.
Thomson.Micromedex. Drug Information for the Health Care Professional. 24th ed. Volume 1. Plus Updates. Content Reviewed by the United States Pharmacopeial Convention, Inc. Greenwood Village, CO. 2004., p. 2132
Omeprazole generally is well tolerated. The most frequent adverse effects associated with omeprazole therapy involve the GI tract (e.g., diarrhea, nausea, constipation, abdominal pain, vomiting) and the CNS (e.g., headache, dizziness).
McEvoy, G.K. (ed.). American Hospital Formulary Service- Drug Information 2004. Bethesda, MD: American Society of Health-System Pharmacists, Inc. 2004 (Plus Supplements)., p. 2839
Diarrhea, abdominal pain, nausea, vomiting, constipation, flatulence, and acid regurgitation are the most frequent adverse GI effects of omeprazole, occurring in about 1-5% of patients. Dysphagia, abdominal swelling, anorexia, irritable colon, fecal discoloration, pancreatitis (sometimes fatal), esophageal candidiasis, mucosal atrophy of the tongue, taste perversion, and dry mouth have been reported occasionally but in many cases were not directly attributed to the drug. Benign gastric fundic polyps have been reported rarely and appear to resolve upon discontinuation of omeprazole therapy.
McEvoy, G.K. (ed.). American Hospital Formulary Service- Drug Information 2004. Bethesda, MD: American Society of Health-System Pharmacists, Inc. 2004 (Plus Supplements)., p. 2840
For more Drug Warnings (Complete) data for OMEPRAZOLE (15 total), please visit the HSDB record page.
Omeprazole, according to the FDA label is a proton pump inhibitor (PPI) used for the following purposes: Treatment of active duodenal ulcer in adults Eradication of Helicobacter pylori to reduce the risk of duodenal ulcer recurrence in adults Treatment of active benign gastric ulcer in adults Treatment of symptomatic gastroesophageal reflux disease (GERD) in patients 1 year of age and older Treatment of erosive esophagitis (EE) due to acid-mediated GERD in patients 1 month of age and older Maintenance of healing of EE due to acid-mediated GERD in patients 1 year of age and older Pathologic hypersecretory conditions in adults
FDA Label
**Effects on gastric acid secretion** This drug decreases gastric acid secretion. After oral administration, the onset of the antisecretory effect of omeprazole is usually achieved within one hour, with the maximum effect occurring by 2 hours after administration. The inhibitory effect of omeprazole on acid secretion increases with repeated once-daily dosing, reaching a plateau after four days. **Effects on serum gastrin** In studies of 200 or more patients, serum gastrin levels increased during the first 1-2 weeks of daily administration of therapeutic doses of omeprazole. This occurred in a parallel fashion with the inhibition of acid secretion. No further increase in serum gastrin occurred with continued omeprazole administration. Increased gastrin causes enterochromaffin-like cell hyperplasia and increased serum Chromogranin A (CgA) levels. The increased CgA levels may lead to false positive results in diagnostic studies for neuroendocrine tumors. **Enterochromaffin-like (ECL) cell effects** Human gastric biopsy samples have been obtained from more than 3000 pediatric and adult patients treated with omeprazole in long-term clinical studies. The incidence of enterochromaffin-like cell hyperplasia in these studies increased with time; however, no case of ECL cell carcinoids, dysplasia, or neoplasia have been identified in these patients. These studies, however, are of insufficient in power and duration to draw conclusions on the possible influence of long-term administration of omeprazole in the development of any premalignant or malignant conditions. **Other effects** Systemic effects of omeprazole in the central nervous system, cardiovascular and respiratory systems have not been found to date. Omeprazole, given in oral doses of 30 or 40 mg for 2-4 weeks, showed no effect on thyroid function, carbohydrate metabolism, or circulating levels of parathyroid hormone, cortisol, estradiol, testosterone, prolactin, cholecystokinin or secretin.
Anti-Ulcer Agents
Various agents with different action mechanisms used to treat or ameliorate PEPTIC ULCER or irritation of the gastrointestinal tract. This has included ANTIBIOTICS to treat HELICOBACTER INFECTIONS; HISTAMINE H2 ANTAGONISTS to reduce GASTRIC ACID secretion; and ANTACIDS for symptomatic relief. (See all compounds classified as Anti-Ulcer Agents.)
Proton Pump Inhibitors
Compounds that inhibit H(+)-K(+)-EXCHANGING ATPASE. They are used as ANTI-ULCER AGENTS and sometimes in place of HISTAMINE H2 ANTAGONISTS for GASTROESOPHAGEAL REFLUX. (See all compounds classified as Proton Pump Inhibitors.)
A02BC01
S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (in prep.). List downloaded from https://cns.public.lu/en/legislations/textes-coordonnes/liste-med-comm.html. Dataset DOI:10.5281/zenodo.4587355
A - Alimentary tract and metabolism
A02 - Drugs for acid related disorders
A02B - Drugs for peptic ulcer and gastro-oesophageal reflux disease (gord)
A02BC - Proton pump inhibitors
A02BC01 - Omeprazole
A - Alimentary tract and metabolism
A02 - Drugs for acid related disorders
A02B - Drugs for peptic ulcer and gastro-oesophageal reflux disease (gord)
A02BC - Proton pump inhibitors
A02BC05 - Esomeprazole
Absorption
Omeprazole delayed-release capsules contain an enteric-coated granule formulation of omeprazole (because omeprazole is acid-labile), so that absorption of omeprazole begins only after the granules exit the stomach. Absorption of omeprazole occurs rapidly, with peak plasma concentrations of omeprazole achieved within 0.5-3.5 hours. Absolute bioavailability (compared with intravenous administration) is approximately 30-40% at doses of 20-40 mg, largely due to pre-systemic metabolism. The bioavailability of omeprazole increases slightly upon repeated administration of omeprazole delayed-release capsules.
Route of Elimination
After a single dose oral dose of a buffered solution of omeprazole, negligible (if any) amounts of unchanged drug were excreted in urine. Most of the dose (about 77%) was eliminated in urine as at least six different metabolites. Two metabolites were identified as _hydroxyomeprazole_ and the corresponding _carboxylic acid_. The remainder of the dose was found in the feces. This suggests significant biliary excretion of omeprazole metabolites. Three metabolites have been identified in the plasma, the _sulfide_ and _sulfone_ derivatives of omeprazole, and _hydroxyomeprazole_. These metabolites possess minimal or no antisecretory activity.
Volume of Distribution
Approximately 0.3 L/kg, corresponding to the volume of extracellular water.
Clearance
Healthy subject (delayed release capsule), total body clearance 500 - 600 mL/min Geriatric plasma clearance: 250 mL/min Hepatic impairment plasma clearance: 70 mL/min
Absorption: rapid. Distribution: Distributed in tissue, particularly gastric parietal cells.
Thomson.Micromedex. Drug Information for the Health Care Professional. 24th ed. Volume 1. Plus Updates. Content Reviewed by the United States Pharmacopeial Convention, Inc. Greenwood Village, CO. 2004., p. 2132
Elimination: Renal 72 to 80%. Fecal 18 to 23%. In dialysis - Not readily dialyzable, because of extensive protein binding.
Thomson.Micromedex. Drug Information for the Health Care Professional. 24th ed. Volume 1. Plus Updates. Content Reviewed by the United States Pharmacopeial Convention, Inc. Greenwood Village, CO. 2004., p. 2132
To clarify the in vivo first-pass metabolism of omeprazole, the pharmacokinetics were examined after oral, intraduodenal, intraportal venous, and intravenous administration at various doses to rats. Extraction ratios in the liver and intestinal tract were determined from the areas under the concentration-time curve (AUC) for intraportal venous and intravenous administration and from those for intraduodenal and intraportal venous administration, respectively. Assuming that the drug was absorbed from the gastrointestinal tract completely, the hepatic and intestinal extraction ratios were 0.80, 0.63, and 0.59 at doses of 2.5, 5, and 10 mg/kg and 0.70 and 0.73 at doses of 5 and 10 mg/kg, respectively. The bioavailability of orally administered omeprazole was 6.4, 9.6, and 12.6% at the doses of l0, 20, and 40 mg/kg, respectively. There were no differences in the distribution volume of steady state, total clearance, or elimination half-life at any doses. In addition, the AUC value after oral administration (20 mg/kg) in rats acutely intoxicated with CC(14) was 2.4 times larger than that in the control. These findings suggest that omeprazole undergoes a first-pass metabolism in the intestinal mucosa and/or lumen, as well as in the liver, and that the major contribution to the dose-dependent increase in bioavailability is a saturation of the first-pass metabolism in the liver.
PMID:7983597 Watanabe K et al; J Pharm Sci 83 (8): 1131-4 (1994)
Omeprazole is distributed into human milk; following oral administration of omeprazole 20 mg in one lactating women, concentrations of the drug were measured in breast milk.
McEvoy, G.K. (ed.). American Hospital Formulary Service- Drug Information 2004. Bethesda, MD: American Society of Health-System Pharmacists, Inc. 2004 (Plus Supplements)., p. 2841
For more Absorption, Distribution and Excretion (Complete) data for OMEPRAZOLE (6 total), please visit the HSDB record page.
Omeprazole is heavily metabolized in the liver by the cytochrome P450 (CYP) enzyme system. The main part of its metabolism depends on the polymorphically expressed CYP2C19, which is responsible for the formation of _hydroxyomeprazole_, the major metabolite found in plasma. The remaining part depends on CYP3A4, responsible for the formation of _omeprazole sulphone_.
The in vitro metabolism of omeprazole was studied in human liver microsomes in order to define the metabolic pathways and identify the cytochrome P450 (CYP) isoforms responsible for the formation of the major omeprazole metabolites. 2 The four major metabolites identified in vitro, in tentative order of importance, were hydroxyomeprazole, omeprazole sulphone, 5-O-desmethylomeprazole, and an unidentified compound termed metabolite X. Omeprazole pyridone was also detected but could not be quantitated. Incubation of hydroxyomeprazole and omeprazole sulphone with human microsomes resulted in both cases in formation of the hydroxysulphone. The kinetics of formation of the four primary metabolites studied were biphasic suggesting the involvement of multiple CYP isoforms in each case. Further studies used substrate concentrations at which the high affinity activities predominated. 3 Formation of the major metabolite, hydroxyomeprazole, was significantly correlated with S-mephenytoin hydroxylase and with benzo[a]pyrene metabolism and CYP3A content. Inhibition studies with isoform selective inhibitors also indicated a dominant role of S-mephenytoin hydroxylase with some CYP3A contribution in the formation of hydroxyomeprazole. Correlation and inhibition data for the sulphone and metabolite X were consistent with a predominant role of the CYP3A subfamily in formation of these metabolites. Formation of 5-O-desmethylomeprazole was inhibited by both R, S-mephenytoin and quinidine, indicating that both S-mephenytoin hydroxylase and CYP2D6 may mediate this reaction in human liver microsomes and in vivo. The Vmax/Km (indicator of intrinsic clearance in vivo) for hydroxyomeprazole was four times greater than that for omeprazole sulphone. Consistent with findings in vivo, the results predict that omeprazole clearance in vivo would be reduced in poor metabolisers of mephenytoin due to reduction in the dominant partial metabolic clearance to hydroxyomeprazole.
PMID:12959268 Full text: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1364656 Andersson T et al; Br J Clin Pharmacol 36 (6): 521-30 (1993)
Omeprazole has known human metabolites that include 3-Hydroxyomeprazole, 5'-O-Desmethyl omeprazole, 5-Hydroxyomeprazole, and Omeprazole sulfone.
S73 | METXBIODB | Metabolite Reaction Database from BioTransformer | DOI:10.5281/zenodo.4056560
0.5-1 hour (healthy subjects, delayed-release capsule) Approximately 3 hours (hepatic impairment)
Plasma - Normal hepatic function - 30 minutes to 1 hour. Chronic hepatic disease - 3 hours.
Thomson.Micromedex. Drug Information for the Health Care Professional. 24th ed. Volume 1. Plus Updates. Content Reviewed by the United States Pharmacopeial Convention, Inc. Greenwood Village, CO. 2004., p. 2132
Hydrochloric acid (HCl) secretion into the gastric lumen is a process regulated mainly by the H(+)/K(+)-ATPase of the proton pump, expressed in high quantities by the parietal cells of the stomach. ATPase is an enzyme on the parietal cell membrane that facilitates hydrogen and potassium exchange through the cell, which normally results in the extrusion of potassium and formation of HCl (gastric acid). Omeprazole is a member of a class of antisecretory compounds, the substituted _benzimidazoles_, that stop gastric acid secretion by selective inhibition of the _H+/K+ ATPase_ enzyme system. Proton-pump inhibitors such as omeprazole bind covalently to cysteine residues via disulfide bridges on the alpha subunit of the _H+/K+ ATPase_ pump, inhibiting gastric acid secretion for up to 36 hours. This antisecretory effect is dose-related and leads to the inhibition of both basal and stimulated acid secretion, regardless of the stimulus. **Mechanism of H. pylori eradication** Peptic ulcer disease (PUD) is frequently associated with _Helicobacter pylori_ bacterial infection (NSAIDs). The treatment of H. pylori infection may include the addition of omeprazole or other proton pump inhibitors as part of the treatment regimen,. _H. pylori_ replicates most effectively at a neutral pH. Acid inhibition in H. pylori eradication therapy, including proton-pump inhibitors such as omeprazole, raises gastric pH, discouraging the growth of H.pylori. It is generally believed that proton pump inhibitors inhibit the _urease_ enzyme, which increases the pathogenesis of H. pylori in gastric-acid related conditions.
Omeprazole is a selective and irreversible proton pump inhibitor. Omeprazole suppresses gastric acid secretion by specific inhibition of the hydrogen-potassium adenosinetriphosphatase (H+, K+-ATPase) enzyme system found at the secretory surface of parietal cells. It inhibits the final transport of hydrogen ions (via exchange with potassium ions) into the gastric lumen. Since the H+/K+ ATPase enzyme system is regarded as the acid (proton) pump of the gastric mucosa, omeprazole is known as a gastric acid pump inhibitor. Omeprazole inhibits both basal and stimulated acid secretion irrespective of the stimulus.
Thomson.Micromedex. Drug Information for the Health Care Professional. 24th ed. Volume 1. Plus Updates. Content Reviewed by the United States Pharmacopeial Convention, Inc. Greenwood Village, CO. 2004., p. 2132
After oral administration, the onset of the antisecretory effect of omeprazole occurs within one hour, with the maximum effect occurring within two hours. Inhibition of secretion is about 50% of maximum at 24 hours and the duration of inhibition lasts up to 72 hours. The antisecretory effect thus lasts far longer than would be expected from the very short (less than one hour) plasma half-life, apparently due to prolonged binding to the parietal H + /K + ATPase enzyme. When the drug is discontinued, secretory activity returns gradually, over 3 to 5 days. The inhibitory effect of omeprazole on acid secretion increases with repeated once-daily dosing, reaching a plateau after four days.
Physicians Desk Reference. 58th ed. Thomson PDR. Montvale, NJ 2004., p. 634
Gonane has API manufacturing expertise in new-age Corticosteroids, Hormones and other pharma raw materials.
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 14969
Submission : 2000-07-31
Status : Inactive
Type : II
Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 34759
Submission : 2020-06-03
Status : Active
Type : II
Certificate Number : CEP 2020-182 - Rev 01
Issue Date : 2024-07-23
Type : Chemical
Substance Number : 942
Status : Valid
Date of Issue : 2024-04-03
Valid Till : 2027-01-21
Written Confirmation Number : WC-0493
Address of the Firm :
NDC Package Code : 42765-010
Start Marketing Date : 2020-06-22
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (25kg/25kg)
Marketing Category : BULK INGREDIENT
Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.
Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
GDUFA
DMF Review : Reviewed
Rev. Date : 2014-02-18
Pay. Date : 2014-01-24
DMF Number : 24640
Submission : 2011-02-16
Status : Active
Type : II
NDC Package Code : 55111-006
Start Marketing Date : 1998-03-25
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Registrant Name : Sungwoo Chemical Co., Ltd.
Registration Date : 2020-03-11
Registration Number : 20150811-52-B-378-18(4)
Manufacturer Name : Dr. Reddy's Laboratories Limited (Unit V)
Manufacturer Address : Unit V, Peddadevulapalli, Tripuraram Mandal, Nalgonda District, Telangana State, India
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 14969
Submission : 2000-07-31
Status : Inactive
Type : II
Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 34759
Submission : 2020-06-03
Status : Active
Type : II
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
GDUFA
DMF Review : Complete
Rev. Date : 2013-03-15
Pay. Date : 2013-03-01
DMF Number : 12917
Submission : 1998-03-25
Status : Active
Type : II
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
GDUFA
DMF Review : Complete
Rev. Date : 2014-02-18
Pay. Date : 2014-01-24
DMF Number : 24640
Submission : 2011-02-16
Status : Active
Type : II
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 19713
Submission : 2006-08-28
Status : Active
Type : II
Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.
GDUFA
DMF Review : Complete
Rev. Date : 2023-08-08
Pay. Date : 2023-07-17
DMF Number : 37449
Submission : 2022-09-29
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2013-08-08
Pay. Date : 2012-11-09
DMF Number : 25621
Submission : 2011-12-22
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 4863
Submission : 1983-03-31
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 11794
Submission : 1995-12-21
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 11017
Submission : 1994-08-02
Status : Inactive
Type : II
Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.
Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.
Certificate Number : CEP 2020-182 - Rev 01
Status : Valid
Issue Date : 2024-07-23
Type : Chemical
Substance Number : 942
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
Certificate Number : R1-CEP 2011-228 - Rev 02
Status : Valid
Issue Date : 2020-08-27
Type : Chemical
Substance Number : 942
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
Certificate Number : R1-CEP 2001-415 - Rev 07
Status : Valid
Issue Date : 2018-06-22
Type : Chemical
Substance Number : 942
Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.
Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.
Certificate Number : CEP 2022-406 - Rev 00
Status : Valid
Issue Date : 2024-06-10
Type : Chemical
Substance Number : 942
Certificate Number : R1-CEP 2002-112 - Rev 03
Status : Valid
Issue Date : 2013-03-28
Type : Chemical
Substance Number : 942
Certificate Number : R0-CEP 2012-116 - Rev 01
Status : Withdrawn by Holder
Issue Date : 2013-03-20
Type : Chemical
Substance Number : 942
Certificate Number : R0-CEP 2002-144 - Rev 01
Status : Expired
Issue Date : 2005-02-08
Type : Chemical
Substance Number : 942
Certificate Number : R0-CEP 2001-048 - Rev 02
Status : Expired
Issue Date : 2005-09-27
Type : Chemical
Substance Number : 942
Certificate Number : R1-CEP 2003-268 - Rev 03
Status : Valid
Issue Date : 2013-04-04
Type : Chemical
Substance Number : 942
Certificate Number : R1-CEP 2000-157 - Rev 03
Status : Valid
Issue Date : 2013-02-13
Type : Chemical
Substance Number : 942
Registration Number : 223MF10050
Registrant's Address : Bhadr-Raj Chambers, Swastik Cross Road, Navrangpura, Ahmedabad-380 009, INDIA
Initial Date of Registration : 2011-04-12
Latest Date of Registration : 2014-10-27
Registration Number : 225MF10073
Registrant's Address : No. 89, 1st Street, Lingbei Road, Lingchuan, Guilin, Guangxi, PR China
Initial Date of Registration : 2013-04-18
Latest Date of Registration : 2013-04-18
Registration Number : 302MF10128
Registrant's Address : 47, Jeyakdanji-ro, Hyangnam-eup, Hwaseong-si, Gyeonggi-do, Republic of Korea
Initial Date of Registration : 2020-10-16
Latest Date of Registration : 2020-10-16
Registration Number : 225MF10127
Registrant's Address : Prilaz baruna Filipovica 25,10000 Zagreb, Croatia
Initial Date of Registration : 2013-07-02
Latest Date of Registration : 2013-07-02
Registration Number : 218MF10191
Registrant's Address : Calle Dulcinea, s/n 28805 Alcala De Henares Madrid Spain
Initial Date of Registration : 2006-02-08
Latest Date of Registration : 2021-11-10
Registration Number : 226MF10185
Registrant's Address : NORTH-EAST OF DONGWAIHUAN ROAD, DONGCHENG INDUSTRIAL AREA, SHOUGUANG CITY, SHANDONG, ...
Initial Date of Registration : 2014-09-30
Latest Date of Registration : 2014-09-30
Omeprazole (for manufacturing purposes only)
Registration Number : 219MF10283
Registrant's Address : Torre Esteve, Pg. de la Zona Franca, 109, 4th floor, 08038 Barcelona - Spain
Initial Date of Registration : 2007-09-10
Latest Date of Registration : 2020-06-08
Registration Number : 219MF10369
Registrant's Address : 148-1 Tajii, Mihara-ku, Sakai City, Osaka Prefecture
Initial Date of Registration : 2007-12-13
Latest Date of Registration : 2007-12-13
OMEPRAZOLE-C EXCLUSIVE USE FOR MANUFACTURE
Registration Number : 306MF10007
Registrant's Address : No. 15 Shuangfeng Road, Fotang, Yiwu, Zhejiang 322002, China
Initial Date of Registration : 2024-01-17
Latest Date of Registration : 2024-01-17
Registration Number : 227MF10109
Registrant's Address : No. 288 Jinqu Road, Jinhua City, Zhejiang, P. R. China
Initial Date of Registration : 2015-04-09
Latest Date of Registration : 2015-04-09
Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.
Date of Issue : 2024-04-03
Valid Till : 2027-01-21
Written Confirmation Number : WC-0493
Address of the Firm : Unit-IV, Plot No. 34B, 40B & 60B, J.N Pharma City, Thanam (V), Parawada (M), Ana...
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
Date of Issue : 2022-06-06
Valid Till : 2025-06-25
Written Confirmation Number : WC-0035a
Address of the Firm : Chemical Technical Operations Unit-V, Plot No 116, Sri Venkateshwara, Jinnaram M...
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
Date of Issue : 2022-06-08
Valid Till : 2025-06-04
Written Confirmation Number : WC-0043Amended
Address of the Firm : Chemical Technical Operations - Unit V, Peddadevulapally Village, Tripuraram Man...
Tagoor's product development expertise, backed by our comprehensive understanding of the processes, helps us offer high-quality APIs.
Date of Issue : 2023-02-14
Valid Till : 2024-02-26
Written Confirmation Number : WC-0494
Address of the Firm : Unit-1, Sy. No.29, Tupakulagudem (Village), Pochavaram Panchayat, Tallapudi (Man...
Date of Issue : 2019-06-26
Valid Till : 2022-06-25
Written Confirmation Number : WC-0023
Address of the Firm : Sy.No.1/22, 2/1 To 5, 6 to 18, 61 to 69, Pydibhimavaram Village, Ranasthalam, Sr...
Date of Issue : 2019-07-22
Valid Till : 2022-07-02
Written Confirmation Number : WC-0135
Address of the Firm : Survey No. 47, Paiki Sub Plot No. 1, Village Lodariyal, Taluka Sanand, Dist. Ahm...
Date of Issue : 2022-09-30
Valid Till : 2025-09-10
Written Confirmation Number : WC-0201
Address of the Firm : T-142, MIDC, Tarapur, Vil: Boisar, Dist: Thane-401 506, Maharashtra State
Date of Issue : 2019-10-28
Valid Till : 2022-06-15
Written Confirmation Number : WC-0371
Address of the Firm : Plot No.59 E, Road No3 Jawaharalal Nehru Pharma City Parawada mandal, Visakhapat...
Date of Issue : 2023-11-20
Valid Till : 2026-05-12
Written Confirmation Number : WC-0176
Address of the Firm : Plot No. 12/A, Phase-III, I.D.A., Jeedimetla, Medichal Malkajigiri Dt, Hyderabad...
Date of Issue : 2022-06-08
Valid Till : 2025-07-25
Written Confirmation Number : WC-0159
Address of the Firm : A-7/A-8, MIDC, Ahmednagar-414 111, Maharashtra State
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
Registrant Name : Sangjin Corporation
Registration Date : 2015-08-11
Registration Number : 20150811-52-B-378-18
Manufacturer Name : Dr. Reddy's Laboratories Lim...
Manufacturer Address : Unit V, Peddadevulapalli, Tripuraram Mandal, Nalgonda District, Telangana State, Indi...
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
Registrant Name : Sungwoo Chemical Co., Ltd.
Registration Date : 2020-03-11
Registration Number : 20150811-52-B-378-18(4)
Manufacturer Name : Dr. Reddy's Laboratories Lim...
Manufacturer Address : Unit V, Peddadevulapalli, Tripuraram Mandal, Nalgonda District, Telangana State, Indi...
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
Registrant Name : Daeshin Pharmaceutical Co., Ltd.
Registration Date : 2017-08-03
Registration Number : 20150811-52-B-378-18(3)
Manufacturer Name : Dr. Reddy's Laboratories Lim...
Manufacturer Address : UnitⅤ, Peddadevulapalli, Tripuraram Mandal, Nalgonda District, Telangana State, Ind...
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
Registrant Name : Chong Kun Dang Co., Ltd.
Registration Date : 2015-11-27
Registration Number : 20150811-52-B-378-18(1)
Manufacturer Name : Dr. Reddy's Laboratories Lim...
Manufacturer Address : Unit V, Peddadevulapalli, Tripuraram Mandal, Nalgonda District, Telangana State, Indi...
Registrant Name : Samoh Pharmaceutical Co., Ltd.
Registration Date : 2006-03-02
Registration Number : 20060302-52-B-228-06
Manufacturer Name : TOWA PHARMACEUTICAL EUROPE, ...
Manufacturer Address : C/de Sant Marti 75-97, 08107 Martorelles, Barcelona, Spain
Registrant Name : Hanseochem Co., Ltd.
Registration Date : 2014-07-04
Registration Number : 20140704-52-B-371-17
Manufacturer Name : Hanseochem Co., Ltd.@[Produc...
Manufacturer Address : 41, Posung Industrial Complex-ro, Pyeongtaek-si, Gyeonggi-do @North-East of Dongwaihu...
Registrant Name : Seongi Bio Co., Ltd.
Registration Date : 2019-09-04
Registration Number : 20190904-52-B-426-19
Manufacturer Name : Lee Pharma Limited
Manufacturer Address : Survey No. 10/G-1, Gaddapotharam Village Jinnaram Mandal, Sangareddy District Telanga...
Registrant Name : Pharmacostec Co., Ltd.
Registration Date : 2020-07-03
Registration Number : 20200703-52-B-435-20
Manufacturer Name : Pharmacostec Co., Ltd.
Manufacturer Address : Block 35-2, Balan Local Industrial Complex, 47, Pharmaceutical Complex, Hyangnam-eup,...
Registrant Name : Chong Kun Dang Co., Ltd.
Registration Date : 2015-03-10
Registration Number : 20050831-52-B-137-02(1)
Manufacturer Name : Esteve Quimica, SA
Manufacturer Address : Poli Industrial El Pla Av. Puigcerda, 9C-17, km 17.4 08185 Llica de Vall (Barcelona) ...
Registrant Name : Sanil Pharma Co., Ltd.
Registration Date : 2012-07-13
Registration Number : 20100915-52-B-297-14(1)
Manufacturer Name : Zhejiang Gold Pharma Co., Lt...
Manufacturer Address : Fanglu Village, Haiyou Town, Sanmen County, Taizhou City, Zhejiang Provine
Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.
NDC Package Code : 42765-010
Start Marketing Date : 2020-06-22
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (25kg/25kg)
Marketing Category : BULK INGREDIENT
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
NDC Package Code : 55111-981
Start Marketing Date : 2015-09-16
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
NDC Package Code : 55111-873
Start Marketing Date : 2006-08-28
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
NDC Package Code : 55111-006
Start Marketing Date : 1998-03-25
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.
NDC Package Code : 62207-983
Start Marketing Date : 2023-01-09
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (20kg/20kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 51552-1050
Start Marketing Date : 2004-09-01
End Marketing Date : 2026-01-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT FOR HUMAN P...
NDC Package Code : 65977-0145
Start Marketing Date : 2008-05-30
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (20kg/20kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 38779-3293
Start Marketing Date : 2023-05-24
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT
NDC Package Code : 53069-0260
Start Marketing Date : 1997-07-23
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 65129-3069
Start Marketing Date : 2002-12-19
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
VMF Number : 5869
Submission : 2006-07-27
Status : Inactive
Type : II
VMF Number : 5629
Submission : 1998-05-22
Status : Active
Type : II
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Details:
Talicia is a novel, fixed-dose combination of two antibiotics (amoxicillin and rifabutin) and a proton pump inhibitor (omeprazole), approved by the U.S. FDA for the treatment of H. pylori infection.
Lead Product(s): Amoxicillin Trihydrate,Rifabutin,Omeprazole
Therapeutic Area: Infections and Infectious Diseases Brand Name: Talicia
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 21, 2024
Lead Product(s) : Amoxicillin Trihydrate,Rifabutin,Omeprazole
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Talicia® Launched in the United Arab Emirates
Details : Talicia is a novel, fixed-dose combination of two antibiotics (amoxicillin and rifabutin) and a proton pump inhibitor (omeprazole), approved by the U.S. FDA for the treatment of H. pylori infection.
Brand Name : Talicia
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 21, 2024
Details:
Talicia is a novel, fixed-dose, all-in-one oral capsule combination of two antibiotics (amoxicillin and rifabutin) and a proton pump inhibitor (PPI) (omeprazole), approved by the U.S. FDA for the treatment of H. pylori infection in adults.
Lead Product(s): Amoxicillin Trihydrate,Rifabutin,Omeprazole
Therapeutic Area: Infections and Infectious Diseases Brand Name: Talicia
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 27, 2023
Lead Product(s) : Amoxicillin Trihydrate,Rifabutin,Omeprazole
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
RedHill Biopharma Announces FDA Grant of 5-Year U.S. Market Exclusivity for Talicia® with IP Prot...
Details : Talicia is a novel, fixed-dose, all-in-one oral capsule combination of two antibiotics (amoxicillin and rifabutin) and a proton pump inhibitor (PPI) (omeprazole), approved by the U.S. FDA for the treatment of H. pylori infection in adults.
Brand Name : Talicia
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 27, 2023
Details:
KONVOMEP™ (omeprazole and sodium bicarbonate for oral suspension) is a medication indicated for short-term treatment (4 to 8 weeks) of active benign gastric ulcer and reduction of risk of upper gastrointestinal bleeding in critically ill adult patients.
Lead Product(s): Omeprazole,Sodium Bicarbonate
Therapeutic Area: Gastroenterology Brand Name: Konvomep
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Azurity Pharma
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 07, 2022
Lead Product(s) : Omeprazole,Sodium Bicarbonate
Therapeutic Area : Gastroenterology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Azurity Pharma
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : KONVOMEP™ (omeprazole and sodium bicarbonate for oral suspension) is a medication indicated for short-term treatment (4 to 8 weeks) of active benign gastric ulcer and reduction of risk of upper gastrointestinal bleeding in critically ill adult patients...
Brand Name : Konvomep
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 07, 2022
Details:
Konvomep™ (omeprazole and sodium bicarbonate for oral suspension) is approved for the treatment of active benign gastric ulcer and reduction of risk of upper gastrointestinal bleeding in critically ill patients.
Lead Product(s): Omeprazole,Sodium Bicarbonate
Therapeutic Area: Gastroenterology Brand Name: Konvomep
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 02, 2022
Lead Product(s) : Omeprazole,Sodium Bicarbonate
Therapeutic Area : Gastroenterology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Azurity Pharmaceuticals, Inc. Announces FDA Approval of Konvomep™ (Omeprazole and Sodium Bicarbo...
Details : Konvomep™ (omeprazole and sodium bicarbonate for oral suspension) is approved for the treatment of active benign gastric ulcer and reduction of risk of upper gastrointestinal bleeding in critically ill patients.
Brand Name : Konvomep
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 02, 2022
Details:
Carlin will be uniquely positioned to acquire and commercialize well-established brands as well as support its retail partners and their customers, in connection with this, Carlin announced the acquisition of Zegerid OTC® (“Zegerid”) from Bayer AG.
Lead Product(s): Omeprazole,Sodium Bicarbonate
Therapeutic Area: Gastroenterology Brand Name: Zegerid
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Carlin Consumer Health
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition February 01, 2022
Lead Product(s) : Omeprazole,Sodium Bicarbonate
Therapeutic Area : Gastroenterology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Carlin Consumer Health
Deal Size : Undisclosed
Deal Type : Acquisition
Details : Carlin will be uniquely positioned to acquire and commercialize well-established brands as well as support its retail partners and their customers, in connection with this, Carlin announced the acquisition of Zegerid OTC® (“Zegerid”) from Bayer AG.
Brand Name : Zegerid
Molecule Type : Small molecule
Upfront Cash : Undisclosed
February 01, 2022
CAS Number : 3173-53-3
End Use API : Omeprazole
About The Company : DKSH, founded with the goal of improving people's lives, assists businesses with market expansion and business growth in both existing and emerging markets. It ...
2-Hydroxymethyl-3,5-dimethyl,4-methoxy pyridine (O...
CAS Number : 86604-78-6
End Use API : Omeprazole
About The Company : Tagoor Laboratories, established in 2018, is a part of the Tagoor Group. It specializes in providing APIs, advanced intermediates and key starting materials for...
2-Chloromethyl-3,5-dimethyl-4-methoxypyridine HCl ...
CAS Number : 86604-75-3
End Use API : Omeprazole
About The Company : Tagoor Laboratories, established in 2018, is a part of the Tagoor Group. It specializes in providing APIs, advanced intermediates and key starting materials for...
5-Methoxy-2[[(4-methoxy-3,5-dimethyl-2-methylpyrid...
CAS Number : 73590-85-9
End Use API : Omeprazole
About The Company : Tagoor Laboratories, established in 2018, is a part of the Tagoor Group. It specializes in providing APIs, advanced intermediates and key starting materials for...
5-Methoxy 2-Mercapto Benzimidazole
CAS Number : 37052-78-1
End Use API : Omeprazole
About The Company : Chemox ChemoPharma Industries was started in 2006 by the eminent entrepreneur Mr. K.H.Vekariya. Today M/s Chemox ChemoPharma Industries is one of the leading m...
2Chloromethyl, 3,5dimethyl 4methoxy pyridine hydro...
CAS Number : 86604-75-3
End Use API : Omeprazole
About The Company : Enal Drugs Private Limited,an ISO 9001 : 2000 certified company, specializes in developing and producing anti ulcerative drugs, their intermediates, other activ...
2(chloromethyl)4methoxy3,5dimethylpyridine hydroch...
CAS Number : 86604-75-3
End Use API : Omeprazole
About The Company : Enal Drugs Private Limited,an ISO 9001 : 2000 certified company, specializes in developing and producing anti ulcerative drugs, their intermediates, other activ...
5Methoxy2[{( 4methoxy3,5dimethyl pyridin2yl) methy...
CAS Number : 73590-85-9
End Use API : Omeprazole
About The Company : Enal Drugs Private Limited,an ISO 9001 : 2000 certified company, specializes in developing and producing anti ulcerative drugs, their intermediates, other activ...
2-Chloromethyl 3,5-Dimethyl 4- methoxy Pyridine Hy...
CAS Number : 86604-75-3
End Use API : Omeprazole
About The Company : Exemed, with due global accreditations from US FDA, KFDA and other regulatory bodies, is one of the leading and cost-competitive manufacturers of Metformin. Bes...
5-Methoxy-2-[[(4-methoxy-3,5- dimethyl-2- pyridyl)...
CAS Number : 73590-85-9
End Use API : Omeprazole
About The Company : Exemed, with due global accreditations from US FDA, KFDA and other regulatory bodies, is one of the leading and cost-competitive manufacturers of Metformin. Bes...
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
Regulatory Info :
Registration Country : Switzerland
Brand Name : Omeprazole Zentiva
Dosage Form : Filmtabl
Dosage Strength : 10mg
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Switzerland
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
Regulatory Info :
Registration Country : Switzerland
Brand Name : Omeprazole Zentiva
Dosage Form : Filmtabl
Dosage Strength : 10mg
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Switzerland
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
Regulatory Info :
Registration Country : Switzerland
Brand Name : Omeprazole Zentiva
Dosage Form : Filmtabl
Dosage Strength : 20mg
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Switzerland
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
Regulatory Info :
Registration Country : Switzerland
Brand Name : Omeprazole Zentiva
Dosage Form : Filmtabl
Dosage Strength : 40mg
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Switzerland
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
Regulatory Info :
Registration Country : Switzerland
Brand Name : Omeprazole Zentiva
Dosage Form : Kaps
Dosage Strength : 10mg
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Switzerland
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
Regulatory Info :
Registration Country : Switzerland
Brand Name : Omeprazole Zentiva
Dosage Form : Kaps
Dosage Strength : 10mg
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Switzerland
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
Regulatory Info :
Registration Country : Switzerland
Brand Name : Omeprazole Zentiva
Dosage Form : Kaps
Dosage Strength : 20mg
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Switzerland
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
Regulatory Info :
Registration Country : Switzerland
Brand Name : Omeprazole Zentiva
Dosage Form : Kaps
Dosage Strength : 20mg
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Switzerland
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
Regulatory Info :
Registration Country : Switzerland
Brand Name : Omeprazole Zentiva
Dosage Form : Kaps
Dosage Strength : 40mg
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Switzerland
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
Regulatory Info :
Registration Country : Switzerland
Brand Name : Omeprazole Zentiva
Dosage Form : Kaps
Dosage Strength : 40mg
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Switzerland
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Company :
Omeprazole
Drug Cost (USD) : 400,220,625
Year : 2022
Prescribers : 7179076
Prescriptions : 27963404
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company :
Omeprazole Magnesium
Drug Cost (USD) : 3,465,356
Year : 2022
Prescribers : 868
Prescriptions : 3768
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company :
Omeprazole/Sodium Bicarbonate
Drug Cost (USD) : 8,461,055
Year : 2022
Prescribers : 262
Prescriptions : 1480
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company :
Omeprazole
Drug Cost (USD) : 439,420,730
Year : 2021
Prescribers : 7145410
Prescriptions : 28270377
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company :
Omeprazole Magnesium
Drug Cost (USD) : 3,155,689
Year : 2021
Prescribers : 968
Prescriptions : 4279
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company :
Omeprazole/Sodium Bicarbonate
Drug Cost (USD) : 7,954,260
Year : 2021
Prescribers : 258
Prescriptions : 1329
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company :
Omeprazole Magnesium
Drug Cost (USD) : 2,992,377
Year : 2020
Prescribers : 1056
Prescriptions : 4502
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company :
Omeprazole
Drug Cost (USD) : 400,599,889
Year : 2020
Prescribers : 7055870
Prescriptions : 28962637
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company :
Omeprazole/Sodium Bicarbonate
Drug Cost (USD) : 8,698,746
Year : 2020
Prescribers : 286
Prescriptions : 1398
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company :
Omeprazole
Drug Cost (USD) : 407,200,690
Year : 2019
Prescribers : 6828406
Prescriptions : 28104430
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
RX/OTC/DISCN : Class B
Dosage Form : Filmtabl
Dosage Strength : 10mg
Price Per Pack (Euro) : 4.96
Published in :
Country : Switzerland
RX/OTC/DISCN : Class B
RX/OTC/DISCN : DISCN
Dosage Form : CAPSULE, DELAYED REL PELLETS;ORA...
Dosage Strength : 10MG
Price Per Pack :
Published in :
Country : USA
RX/OTC/DISCN : DISCN
RX/OTC/DISCN :
Dosage Form : Gastro-Resistant Hard Capsules
Dosage Strength : 10 mg
Price Per Pack (Euro) : 3.09
Published in :
Country : Italy
RX/OTC/DISCN :
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
RX/OTC/DISCN : Class B
Dosage Form : Caps
Dosage Strength : 10mg
Price Per Pack (Euro) : 5.94
Published in :
Country : Switzerland
RX/OTC/DISCN : Class B
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
RX/OTC/DISCN : Class B
Dosage Form : Caps
Dosage Strength : 20mg
Price Per Pack (Euro) : 3.46
Published in :
Country : Switzerland
RX/OTC/DISCN : Class B
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
RX/OTC/DISCN : Class B
Dosage Form : Caps
Dosage Strength : 20mg
Price Per Pack (Euro) : 12.51
Published in :
Country : Switzerland
RX/OTC/DISCN : Class B
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
RX/OTC/DISCN : Class B
Dosage Form : Caps
Dosage Strength : 20mg
Price Per Pack (Euro) : 24.15
Published in :
Country : Switzerland
RX/OTC/DISCN : Class B
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
RX/OTC/DISCN : Class B
Dosage Form : Caps
Dosage Strength : 40mg
Price Per Pack (Euro) : 4.9
Published in :
Country : Switzerland
RX/OTC/DISCN : Class B
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
RX/OTC/DISCN : Class B
Dosage Form : Filmtabl
Dosage Strength : 10mg
Price Per Pack (Euro) : 8.29
Published in :
Country : Switzerland
RX/OTC/DISCN : Class B
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
RX/OTC/DISCN : Class B
Dosage Form : Filmtabl
Dosage Strength : 10mg
Price Per Pack (Euro) : 16.89
Published in :
Country : Switzerland
RX/OTC/DISCN : Class B
Market Place
Reply
11 Oct 2024
Reply
28 Sep 2024
Reply
03 Aug 2024
Reply
25 Jul 2024
Reply
06 Jun 2024
Reply
08 Mar 2024
Reply
20 Sep 2023
Reply
25 Jul 2023
Reply
09 Feb 2023
Reply
19 Jan 2023
Patents & EXCLUSIVITIES
Patent Expiration Date : 2039-07-16
OMEPRAZOLE; SODIUM BICARBONATE
US Patent Number : 11911473
Drug Substance Claim :
Drug Product Claim :
Application Number : 213593
Patent Use Code : U-623
Delist Requested :
Patent Use Description : SHORT TERM TREATMENT O...
Patent Expiration Date : 2039-07-16
Patent Expiration Date : 2039-07-16
OMEPRAZOLE; SODIUM BICARBONATE
US Patent Number : 12042539
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 213593
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2039-07-16
Patent Expiration Date : 2039-07-16
OMEPRAZOLE; SODIUM BICARBONATE
US Patent Number : 11633478
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 213593
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2039-07-16
Patent Expiration Date : 2039-07-16
OMEPRAZOLE; SODIUM BICARBONATE
US Patent Number : 11103492
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 213593
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2039-07-16
Patent Expiration Date : 2025-08-16
US Patent Number : 9023391
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 22032
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2025-08-16
Patent Expiration Date : 2033-01-02
US Patent Number : 9987231
Drug Substance Claim :
Drug Product Claim :
Application Number : 205103
Patent Use Code : U-2324
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2033-01-02
Patent Expiration Date : 2033-03-13
US Patent Number : 9539214
Drug Substance Claim :
Drug Product Claim :
Application Number : 205103
Patent Use Code : U-1902
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2033-03-13
Patent Expiration Date : 2033-01-02
US Patent Number : 9987231
Drug Substance Claim :
Drug Product Claim :
Application Number : 205103
Patent Use Code : U-2324
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2033-01-02
Patent Expiration Date : 2016-02-09
Date Granted : 2002-04-16
Brand Name : LOSEC
Patent Number : 2186037
Filing Date : 1996-02-09
Strength per Unit : 20mg
Dosage Form : Capsule
Human Or VET : Human
Route of Administration : Oral
Patent Expiration Date : 2016-02-09
Date Granted : 2002-04-16
Patent Expiration Date : 2013-04-20
Date Granted : 2000-08-01
Brand Name : LOSEC
Patent Number : 2133762
Filing Date : 1993-04-20
Strength per Unit : 20mg
Dosage Form : Capsule
Human Or VET : Human
Route of Administration : Oral
Patent Expiration Date : 2013-04-20
Date Granted : 2000-08-01
Patent Expiration Date : 2013-06-11
Date Granted : 1996-06-11
Brand Name : LOSEC
Patent Number : 1338377
Filing Date : 1987-02-12
Strength per Unit : 20mg
Dosage Form : Capsule
Human Or VET : Human
Route of Administration : Oral
Patent Expiration Date : 2013-06-11
Date Granted : 1996-06-11
Patent Expiration Date : 2013-04-20
Date Granted : 2000-08-01
Brand Name : LOSEC
Patent Number : 2133762
Filing Date : 1993-04-20
Strength per Unit : 40mg
Dosage Form : Capsule
Human Or VET : Human
Route of Administration : Oral
Patent Expiration Date : 2013-04-20
Date Granted : 2000-08-01
Patent Expiration Date : 2013-06-11
Date Granted : 1996-06-11
Brand Name : LOSEC
Patent Number : 1338377
Filing Date : 1993-09-14
Strength per Unit : 40mg
Dosage Form : Capsule
Human Or VET : Human
Route of Administration : Oral
Patent Expiration Date : 2013-06-11
Date Granted : 1996-06-11
Patent Expiration Date : 2013-04-20
Date Granted : 2000-08-01
Brand Name : LOSEC
Patent Number : 2133762
Filing Date : 1993-04-20
Strength per Unit : 10mg
Dosage Form : Capsule
Human Or VET : Human
Route of Administration : Oral
Patent Expiration Date : 2013-04-20
Date Granted : 2000-08-01
Patent Expiration Date : 2013-06-11
Date Granted : 1996-06-11
Brand Name : LOSEC
Patent Number : 1338377
Filing Date : 1987-02-12
Strength per Unit : 10mg
Dosage Form : Capsule
Human Or VET : Human
Route of Administration : Oral
Patent Expiration Date : 2013-06-11
Date Granted : 1996-06-11
Patent Expiration Date : 2018-11-10
Date Granted : 2002-02-26
Brand Name : LOSEC
Patent Number : 2284470
Filing Date : 1998-11-10
Strength per Unit : 20mg
Dosage Form : Capsule
Human Or VET : Human
Route of Administration : Oral
Patent Expiration Date : 2018-11-10
Date Granted : 2002-02-26
Patent Expiration Date : 2014-01-05
Date Granted : 2004-03-23
Brand Name : LOSEC
Patent Number : 2180535
Filing Date : 1994-01-05
Strength per Unit : 20mg
Dosage Form : Capsule
Human Or VET : Human
Route of Administration : Oral
Patent Expiration Date : 2014-01-05
Date Granted : 2004-03-23
Patent Expiration Date : 2018-11-10
Date Granted : 2002-02-26
Brand Name : LOSEC
Patent Number : 2284470
Filing Date : 1998-11-10
Strength per Unit : 10mg
Dosage Form : Capsule
Human Or VET : Human
Route of Administration : Oral
Patent Expiration Date : 2018-11-10
Date Granted : 2002-02-26
REF. STANDARDS & IMPURITIES
Omeprazole for peak identification
Omeprazole for peak identification
CAS Number : 73590-58-6
Quantity Per Vial : 10 mg
Sale Unit : 1
Order Code : Y0001042
Batch No : 2
Price (€) : 79
Storage : -20°C ± 5°C
Omeprazole impurity D
CAS Number : 88546-55-8
Quantity Per Vial : 15 mg
Sale Unit : 1
Order Code : O0151000
Batch No : 3
Price (€) : 79
Storage : -20°C ± 5°C
Omeprazole
CAS Number : 73590-58-6
Quantity Per Vial : 50 mg
Sale Unit : 1
Order Code : O0150000
Batch No : 5
Price (€) : 79
Storage : -20°C ± 5°C
Omeprazole Related Compound I (15 mg) (4-Meth...
CAS Number : 158812-85-2
Quantity Per Vial :
Price ($) : 805
Catalog Number : 1478561
Current Lot : F2M516
Previous Lot : F1M516 (31-JAN-2017)
NDC Code :
Omeprazole Related Compound E (15 mg) (4-Meth...
CAS Number : 176219-04-8
Quantity Per Vial :
Price ($) : 730
Catalog Number : 1478527
Current Lot : R04730
Previous Lot : F2M515 (30-JUN-2017)
NDC Code :
Omeprazole Related Compound F and G Mixture (...
CAS Number : N/A
Quantity Per Vial :
Price ($) : 730
Catalog Number : 1478491
Current Lot : R074L0
Previous Lot : F1K420 (30-SEP-2018)
NDC Code :
Omeprazole Related Compound B (15 mg) (5-Meth...
CAS Number : 37052-78-1
Quantity Per Vial :
Price ($) : 730
Catalog Number : 1478480
Current Lot : R03690
Previous Lot : F00670 (30-NOV-2016)
NDC Code :
ANALYTICAL
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?